{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002822","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.098585+00:00","generated_at":"2026-06-07T02:46:31.934163+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sarepta prelim FY2023 net product rev $1.145B; ELEVIDYS $200.4M beats consensus","bullets":["Preliminary FY2023 total net product revenue of ~$1.145B; RNA PMOs $945.0M (above $925M guidance).","ELEVIDYS net product revenue of $131.3M in Q4 and $200.4M for FY2023, significantly exceeding consensus.","RNA-based PMO net revenue of $234.3M in Q4 and $945.0M for FY2023.","Preliminary cash, equivalents, restricted cash and investments of ~$1.7B as of Dec 31, 2023.","Company to report final Q4/FY2023 results in late February 2024; results subject to adjustment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002822","json":"https://secwatch.observer/filing/0000950170-24-002822.json","markdown":"https://secwatch.observer/filing/0000950170-24-002822.md","text":"https://secwatch.observer/filing/0000950170-24-002822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/0000950170-24-002822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/srpt-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:46:31.934163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1eeb4e8232983c2d341c932545a4f16142688e40","claim":"Sarepta Therapeutics, Inc. reported the year ended December 31, 2023 results: revenue $1.145 billion.","evidence_excerpt":"the Company disclosed its (unaudited) cash position of approximately $1.7 billion as of December 31, 2023, and that the Company generated approximately $1.145 billion in total net product revenue (unaudited) in the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/0000950170-24-002822-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$1.145 billion"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}